Minor progress has been made via high-throughput drug screens in several tumors including cyclin-dependent kinase 1/2 (CDK1/2)-, polo-like kinase 1 (PLK1)-, and WEE1-mutated cancers. This evidence concerns the gene PLK1 and cancer.